Investors in Exact Sciences went on a selling spree after CellMax publicized data suggesting its test could outperform Cologuard for the early detection of colorectal cancer.
The Index also outperformed the Dow Jones, the Nasdaq, and the Nasdaq Biotechnology Index, all of which also showed double-digit percentage growth.
The Index underperformed the Dow, Nasdaq, and Nasdaq Biotechnology Index, reversing gains it had made in October and November.
OpGen had previously been warned by Nasdaq that it failed to meet listing requirements. Last week, the firm was told that it was ineligible for an extension to regain compliance.
The investment bank previously had a Neutral rating for the company, and it lowered the price target on Genomic Health's stock to $25 from $28.
The Index significantly outperformed the Dow, Nasdaq, and Nasdaq Biotechnology Index as it showed double the growth that it had displayed in October.
Thermo Fisher said that it received notice that TRC Capital made an unsolicited mini-tender offer to purchase up to 1 million shares of its stock at $181.75 per share.
The index gained more than 3 percent, significantly outperforming the Nasdaq Biotechnology Index, but slightly underperforming the Dow and Nasdaq.
The index gained 1 percent, outperforming the Nasdaq Biotechnology Index, but underperforming the Dow, which gained 2 percent.
The Index gained 4 percent, outperforming the Dow and the Nasdaq, but underperformed the Nasdaq Biotechnology Index, which rose 5 percent.
Retraction Watch reports that a paper was pulled because it refers to a gene that doesn't exist in mice.
Researchers were able to generate fertilized northern white rhinoceros eggs, according to Mashable.
Former Orig3n employees raise concerns about its testing at Bloomberg Businessweek.
In PLOS this week: microRNA expression changes in hepatocellular carcinoma, real-time PCR-based approach for diagnosing schistosomiasis, and more.